Skip to content
Menu
Home
Purpose
People
Portfolio
Press
Participate
Press
All
Bioluminescence News
Portfolio News
Events
Portfolio
-
Press Releases
Ensoma Unveils Three Programs Leveraging In Vivo Hematopoietic Stem Cell Engineering Platform to Target Genetic, Immune and Oncological Diseases
November 5, 2024
Nov 5, 2024
Portfolio
-
Press Releases
Ensoma Appoints Accomplished Deal Maker Jon Garen as Chief Corporate Development and Business Officer
October 28, 2024
Oct 28, 2024
Portfolio
-
Press Releases
Nido Biosciences Announces Orphan Drug Designation for Lead Clinical Candidate to Treat Spinal and Bulbar Muscular Atrophy
October 22, 2024
Oct 22, 2024
Portfolio
-
Press Releases
Cerevance Announces Publication of Positive Phase 2 Results of Solengepras for the Treatment of Parkinson’s Disease in eClinical Medicine
October 21, 2024
Oct 21, 2024
Portfolio
-
Press Releases
Cerevance Achieves Second Milestone in Research Collaboration with Merck
October 8, 2024
Oct 8, 2024
Portfolio
-
Press Releases
ReCode Announces Two Key Additions to Scientific Advisory Board
October 1, 2024
Oct 1, 2024
Portfolio
-
Press Releases
ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic Fibrosis
September 26, 2024
Sep 26, 2024
Portfolio
-
Press Releases
Cerevance Appoints Sagar Vaidya, M.D. Ph.D., as Chief Medical Officer
August 12, 2024
Aug 12, 2024
Portfolio
-
Press Releases
ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia
June 27, 2024
Jun 27, 2024
Portfolio
-
Press Releases
New Article Published in Science Highlights the Potential of ReCode Therapeutics’ Systemic Lung Delivery and CFTR Gene Correction
June 13, 2024
Jun 13, 2024
1
2
3